Background: Lung density measurements by computed tomography have previously been found to be a more sensitive indicator of disease progression in emphysema of α1-antitrypsin deficiency than lung function measurements. The aim of this study was to investigate the predictive potential of several parameters, including CT scanning, for mortality in patients with severe α1-antitrypsin deficiency.
Methods: Over a 5 year period, 256 patients with α1-antitrypsin deficiency (PiZ phenotype) were assessed, of whom 254 underwent lung function testing and 197 had thoracic CT scans. Lung function, CT scans, health status (St George’s Respiratory Questionnaire, SGRQ), and other clinical data of survivors and non-survivors were compared and these parameters were applied to survival analyses.
Results: There were 22 deaths in this patient cohort, 10 of which were classified as “respiratory” deaths. Baseline lung function parameters (forced expiratory volume in 1 second (FEV1), carbon monoxide transfer coefficient (Kco)), and CT scores were significantly lower in the non-survivors than in the survivors. 170 of the 256 patients had complete data for entry into multiple regression analyses (Cox proportional hazards model). In the univariate analysis, upper zone expiratory scan had the best association with all cause (p = 0.001) and respiratory mortality (p<0.001), whereas FEV1 (p = 0.158 all cause, 0.015 respiratory) and Kco (p = 0.002 all cause, 0.012 respiratory) had poorer associations with mortality. Only age gave further independent predictive information regarding all cause or respiratory mortality when the CT scan was entered into the survival analyses.
Conclusions: CT scanning predicts respiratory and all cause mortality in α1-antitrypsin deficiency and appears to be superior to lung function parameters, especially FEV1.
- lung densitometry
- α1-antitrypsin deficiency
- computed tomography
- outcome measures
Statistics from Altmetric.com
The α1-antitrypsin deficiency assessment programme in Birmingham is supported by a non-commercial grant from Bayer plc.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.